CELL REPORTS MEDICINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2025-02-06 ms8000001004840434 来自天津

审稿速度:24.0 | 投稿命中率:25.0
偏重的研究方向：药理转化
经验分享：投稿第七天终于UR，期待会有好结果~

18 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2025-05-12 ms1000001449915384 来自浙江省

投稿28天，还在with editor

1 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2025-03-19 yuya_wang 来自北京

审稿速度:12.0 | 投稿命中率:25.0
偏重的研究方向：动物模型;感染机制;虫媒病毒
经验分享：投稿2周了一直with editor，不知道什么情况？

12 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2025-03-09 4261225_2083 来自上海

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤学
经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。

13 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2024-07-08 易挥发来自广东省

审稿速度:12.0 | 投稿命中率:25.0
偏重的研究方向：外泌体;肿瘤标志物
经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间

245 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2024-12-16 ms3000000483285706 来自美国

审稿速度:3.0 | 投稿命中率:50.0
经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划

26 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2025-03-19 ms5000002977722152 来自上海

期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。
平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。

12 0

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2024-03-19 ms6000001492149190 来自山东省

审稿速度:12.0 | 投稿命中率:5.0
偏重的研究方向：基因治疗;眼科学
经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人

298 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2025-01-07 Charlo 来自安徽省

编辑预审过了，正式投稿拒了，浪费感情。

0 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2250684, encodeId=7ee6225068413, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：药理转化 经验分享：投稿第七天终于UR，期待会有好结果~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5a9413200, createdName=ms8000001004840434, createdTime=Thu Feb 06 08:19:46 CST 2025, time=2025-02-06, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2264700, encodeId=e3762264e002f, content=投稿28天，还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf18629552, createdName=ms1000001449915384, createdTime=Mon May 12 20:24:02 CST 2025, time=2025-05-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2256758, encodeId=399c2256e5821, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：动物模型;感染机制;虫媒病毒 经验分享：投稿2周了一直with editor，不知道什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f0d3130102, createdName=yuya_wang, createdTime=Wed Mar 19 15:16:06 CST 2025, time=2025-03-19, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2255326, encodeId=7c7b225532631, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：cell旗下一稿多投选了mc和crm，crm编辑愿意送审，mc直接拒稿，转投crm后一个月回来意见，三个审稿人意见很犀利，编辑要讨论修回plan，plan中一条argue的意见编辑觉得太敷衍，要求follow up这个问题，re-battle后编辑同意我们battle并提示如果时间不够可以延长修回时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdd96318155, createdName=4261225_2083, createdTime=Sun Mar 09 15:42:33 CST 2025, time=2025-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2213875, encodeId=772522138e5f5, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：2023.9投稿，中间催了几次，2024.1返回意见，3个reviewer的意见都还比较正向，但是编辑的态度比较负面，让我们准备好修改计划发给编辑部评估再决定是否resubmit，一个礼拜后直接发给编辑修改计划，过了一个月才回复同意resubmit。。。2024.2返修，2024.6 3个reviewer基本同意接收，补充方法学细节后pre-accepting。总之就是非常慢，前后花费10个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Mon Jul 08 13:02:42 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2242937, encodeId=df2d224293eb9, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：24.11.1投的，中间一直没有消息。24.12.12给了大修。编辑让讨论修回计划, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9a9572348, createdName=ms3000000483285706, createdTime=Mon Dec 16 16:12:37 CST 2024, time=2024-12-16, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2256816, encodeId=9f2c2256816cb, content=期刊2023年的影响因子为14.3，中科院一区，分区为Q1，主要涵盖分子医学、细胞生物学、临床医学、免疫学、感染病学及生物医学工程等前沿领域。 平均审稿周期约为3个月，但整体出版周期还是比较长的，适合不急于发表的研究，像转化医学、临床生物医学等适合。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722152, createdTime=Wed Mar 19 22:57:31 CST 2025, time=2025-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194011, encodeId=5d43219401120, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：基因治疗;眼科学 经验分享：我真是服了这个垃圾杂志了，编辑很墨迹，第一次投之后审稿时间很长，差不多3个月，催了才给的回复，三个审稿人，2个拒1个大修，我们的研究跟药物可能有点冲突，然后跟编辑battle了一下，编辑同意再次审核。大修之后2个审稿人没有任何意见，但是有一个审稿人一看就是傻逼，完全没有看我们文章的内容和我们对文章的完善，还是给了个拒。然后编辑还是给的拒。真应该去手刃了那个傻逼审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=298, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d87a6445676, createdName=ms6000001492149190, createdTime=Tue Mar 19 09:49:18 CST 2024, time=2024-03-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2246992, encodeId=6494224699259, content=编辑预审过了，正式投稿拒了，浪费感情。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Jan 07 19:38:21 CST 2025, time=2025-01-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0 偏重的研究方向：临床医学 经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海)]

2023-06-28 yo3333 来自上海

审稿速度:4.0
偏重的研究方向：临床医学
经验分享：cell新子刊，看近期的文章质量，往20分去的。有幸中了一篇，历时7个月，本人肿瘤方向，主要做的临床样本和机制。前期慢的都想溜了，还好耐心等下去了

5 12

展开12条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务